BRINGING HEALTH INSIGHT

TREAT THE
UNTREATABLE

Our pipeline of novel therapies, which is built on our RBP4 (Retinol Binding Protein 4) IP Portfolio, is focused on meeting the unmet needs of patients suffering from blindness, liver disease and diabetes.

Novel Therapy for

UNMET MEDICAL NEED

Belite Bio™ is a San Diego based clinical stage biopharmaceutical drug development company targeting untreatable eye diseases, such as atrophic age-related macular degeneration (commonly known as dry AMD) and Stargardt disease, and metabolic diseases.

Developed from our RBP4 intellectual property portfolio, our lead candidate, LBS-008, has initiated its phase 3 for Stargardt disease, an inherited juvenile form of macular degeneration, and expects to initiate its phase 3 for dry age-related macular degeneration in 2022. LBS-008 has obtained Orphan Drug Designation in the United States and Europe and has been granted a Rare Pediatric Disease (RPD) designation and Fast Track Designation in the US.

 

LBS

008

Tinlarebant

Bringing Hope to

INCURABLE BLINDNESS

Dry AMD









PHASE 3
Stargardt Disease









PHASE 3

LBS

009

Blocking the Path to

METABOLIC DISEASE

Non-Fatty Liver Disease / Type 2 Diabetes

PRECLINICAL

i
Patient Registry

Select Your Preferred Language:

LBS-008 – Phase 3 trial for Stargardt Disease (the “Dragon” trial)

Recruitment Status : Recruiting

This trial is to assess the efficacy and safety of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.

LBS-008 – Phase 1b/2 trial for Stargardt Disease

Recruitment Status : Active, not recruiting

This Phase 1b trial is to identify the optimal dose of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease. The Phase 1b trial is extended to a two year Phase 2 trial in assessing the safety and efficacy of Tinlarebant in adolescent subjects with childhood-onset Stargardt Disease.